Immunology
McMaster, Sartorius partner on improving biomanufacturing
Sartorius Stedim Biotech and McMaster University, which is located in Hamilton, Ontario, Canada, plan to collaborate on an effort to improve advanced manufacturing processes for antibody and virus-based treatments for diseases like COVID-19 and cancer. Read More
Abcam to purchase BioVision for $340M
Custom antibody developer Abcam plans to purchase biotechnology firm BioVision for $340 million. Read More
Scientists visualize viruses in motion using advanced electron microscopy
Advanced electron microscopy has enabled researchers to visualize how human viruses move in high resolution in a near-native environment. The visualization technique, published in Advanced Materials on July 24, could lead to an improved understanding of the molecular mechanisms of vaccines and therapeutics. Read More
Amgen to buy private firm Teneobio for $900M
Amgen will spend $900 million in cash to acquire the privately held biotechnology company Teneobio, which is developing a new class of biologics known as human heavy-chain antibodies. Read More
FDA issues EUA for monoclonal antibody for treatment of hospitalized COVID-19 patients
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) to Genentech, a member of the Roche Group, for tocilizumab (Actemra) for the treatment of hospitalized adults and pediatric patients. Read More
Collaboration targets new treatments for brain diseases
Developing more effective methods to deliver drugs across the blood-brain barrier is the goal of a new collaboration being led by the Wyss Institute for Biologically Inspired Engineering at Harvard University. Read More
Leveraging past flu pandemics helps build universal flu vaccine
Targeting regions of the influenza virus that do not often change may be an effective strategy for developing next-generation universal flu vaccines, according to new research published in Science Translational Medicine on June 2. Researchers interrogated immune responses from the 2009 H1N1 influenza pandemic to determine which targets to include in new vaccines. Read More
Single-cell study discovers how antibody regulators develop in tissue
The development process of immune cells important for establishing long-term immunity has been revealed through detailed single-cell techniques. A new study, published in the journal Science Immunology on May 28, examined extracted tonsils and lymph nodes to establish how human T follicular cells specialize in the body. Read More
Leveraging optofluidics to make therapeutic antibody discovery easier
The need for speed and accuracy in the development of therapeutic antibodies has prompted Berkeley Lights to upgrade its optofluidic tools to help customers improve the quality of their therapeutic antibody products. John Proctor, PhD, senior vice president of antibody therapeutics at Berkeley Lights, spoke with ScienceBoard.net about some technological advancements the company has recently launched. Read More
Hope for next-gen COVID-19 vaccines may rest in an unexpected region of the virus
Researchers further elucidated how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus responsible for causing infection. The study, published in Science on May 4, describes how antibodies targeting sections of the virus outside of the receptor-binding domain may be useful in the development of vaccines and therapies. Read More
Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter